# KEYNOTE-564 (NCT03142334)

> Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03142334
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Renal Cell Carcinoma
- Interventions: Pembrolizumab; Placebo
- Enrollment: 994
- Primary outcome: Disease-free Survival (DFS) as Assessed by the Investigator

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 182
- YouTube: 112
- Podcasts: 86
- X videos: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=keynote-564-nct03142334

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03142334", "email": "<work email>"}; the inbox owner confirms by the emailed link.